180 Life Sciences Corp

Aktienanalyse zu 180 Life Sciences Corp (ATNF)

$7.040

-0.527 (-7.49%)Zum Schluss

Loading chart…
High
7.240
Open
6.840
VWAP
6.86
Vol
11.63M
Mkt Cap
1.43M
Low
6.290
Amount
79.77M
EV/EBITDA, TTM
0.00

180 Life Sciences Corp. is a biotechnology company, which focuses on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. Its programs include Anti-TNF (Clinical), Synthetic Cannabinoid Analogs (SCAs), and a7nAChR (Preclinical). The Company also operates a back-end technology platform to operate an online blockchain casino.

Bewertungskennzahlen

The current forward P/E ratio for 180 Life Sciences Corp (ATNF) is -0.01, compared to its 5-year average forward P/E of -9.42.

Forward P/E

Fair
5Y Average P/E
-9.42
Current P/E
-0.01
Überbewertet
25.00
Unterbewertet
-43.85

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Überbewertet
0.00
Unterbewertet
0.00

Forward P/S

Fair
5Y Average P/S
4.28
Current P/S
0.19
Überbewertet
16.51
Unterbewertet
-7.96

ATNF FAQ — answered by Alphio AI

180 Life Sciences Corp. is a biotechnology company, which focuses on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. Its programs include Anti-TNF (Clinical), Synthetic Cannabinoid Analogs (SCAs), and a7nAChR (Preclinical). The Company also operates a back-end technology platform to operate an online blockchain casino. It operates in the Technology sector (PHARMACEUTICAL PREPARATIONS industry).

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten